Antiretroviral Drug Resistance Anna Maria Geretti UCL Medical School & Royal Free Hampstead Medical School, London.

Slides:



Advertisements
Similar presentations
Antiretroviral Drug Resistance
Advertisements

Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
HIV and its lifecycle Sources: Wikipedia, HIV is a retrovirus (enveloped viruses possessing an RNA genome,
V IRAL R EPLICATION. V IRUS Like live organisms: need to replicate and create progeny. Unlike organisms: A virus cannot survive on its own. It is only.
Viruses, part 2.
VIRAL REPLICATION Dr AYMAN JOHARGY 3 rd Year Medicine Clinical Microbiology 2 nd Semester Lecture 2 3 rd Year Medicine Clinical Microbiology 2 nd Semester.
HIV and AIDS Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immunodeficiency Syndrome (AIDS).
Viruses.
HIV Structure, Lifecycle, and Replication
Chemistry: An Introduction to General, Organic, and Biological Chemistry, Eleventh Edition Copyright © 2012 by Pearson Education, Inc. Chapter 17 Nucleic.
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
ARV Nurse Training, Africaid, 2004 ARV Nurse Training Programme Marcus McGilvray & Nicola Willis About Resistance.
Global HIV Resistance: The Implications of Transmission
HIV and AIDS Human Immunodeficiency Virus (HIV) causes Acquired Immune Deficiency Syndrome (AIDS)
Viruses.
Viruses. Virus: Particles of nucleic acid, protein, some lipids Reproduce vicariously Use the cells they infect to build new viruses.
 Viruses (2) Biology 11 Mr. McCallum. What do viruses do?  Replicate, replicate, replicate!  Harmful as this leads to the death of the host cell 
Viruses. What are Viruses? Virus – particles of nucleic acid, protein, and in some cases lipids –Not alive –Do NOT exhibit characteristics of life –Can.
Virus = virion 1. Living characteristics of viruses: They reproduce at a fantastic rate, but only in living host cells. They can mutate. 2. Nonliving characteristics.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display The Steps in HIV Replication Slide number 1 (1) Viral.
Viruses. Virus A non living particle composed of a nucleic acid and a protein coat A non living particle composed of a nucleic acid and a protein coat.
Unit 11 – Viruses, Bacteria, and Protist
Virus Structure and Method of Invasion Higher Biology.
Microbiology Ch 17.1: Viruses 17.2: Monera. Virus: A non- cellular particle made up of genetic material and protein that can invade cells.
Chelsea Harmon Catherine Hanson Abby Llaneza Jen Williams
Chapter 23: Viruses Leaving Certificate Biology Higher Level.
ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.
Viruses Virus: A noncellular particle composed of genetic material that can invade living cells. –Viruses are considered by most to be non- living since.
HIV Life Cycle Step 1: Fusion Step 2: Transcription reverse transcriptase Step 3: Integration Step 4: Cleavage Step 5: Packaging and Budding HIV.
Viruses Mader-Chapter 21.
Virology - study of viruses
HIV.
Immune reconstitution Anjie Zhen, PhD
Genetics of Viruses. Viral Structure n Virus: – “poison” (Latin) – infectious particles consisting of a nucleic acid in a protein coat n Capsid= viral.
The HIV virus. Objectives At the end of this session the participants will be able to: 1. Understand basic HIV structure 2. Describe the significance.
Infection STrategies Lytic Cycle: – The virus enters the cell, makes copies of itself and causes the cell to burst. Uses the materials and cell machinery.
Other biological particles.   Non-cellular infectious agent  Characteristics of all viruses  1) protein coat wrapped around DNA or RNA  2) cannot.
General, Organic, and Biological Chemistry Copyright © 2010 Pearson Education, Inc Viruses Chapter 21 Nucleic Acids and Protein Synthesis.
Major Parts of a Virus - Bacteriophage
Viruses. Classifying Viruses How to tell them apart.
Reproduce They have DNA or RNA They can adapt to surroundings The have organization They are not made of cells or organelles They cannot reproduce without.
Antivirals Essential idea
Viruses Virus: A noncellular particle composed of genetic material that can invade living cells. Viruses are considered by most to be non-living since.
Biology/O’Connor Virus/Bacteria Notes
Chapter Viruses.
AIDS supplement.
Bacteria and Viruses Viruses.
Tuesday 4/26/16 Learning Target: Know the characteristics, reproduction and how to control viruses. Learning Outcome: Create a virus of your choice which.
Antivirals Essential idea
AIM: How does HIV cause someone to get sick?
Bacteria and Viruses Viruses.
Hiv.
Abnormal Immunity Continued
Viruses.
Viral Structure, Lifecycles, HIV
Viruses.
Virus Notes Chapter 19 Section 19-2.
Virus Notes Chapter 19 Section 19-2.
Turner College & Career High School  2016
Viruses.
Viruses Virus: A noncellular particle composed of genetic material that can invade living cells. Viruses are considered by most to be non-living since.
Viruses Dead or alive?.
Chapter 15 Viruses, Viral Life Cycles, Retroviruses.
Viruses.
Viruses Dead or alive?.
Virus Notes.
Terminology HIV AIDS Acquired Human Immune Immunodeficiency Deficiency
Virus A pathogen that consists of a Nucleic Acid – (DNA or RNA) wrapped in a Protein Coat- (Capsid). Classification: Classified by the host Bacteriophage.
Viruses TEK 4C: Compare structures of viruses to cells, describe viral reproduction, and describe the role of viruses in causing diseases such as HIV and.
The hantavirus life cycle.
Presentation transcript:

Antiretroviral Drug Resistance Anna Maria Geretti UCL Medical School & Royal Free Hampstead Medical School, London

Drug-related factors Potency PK properties Genetic barrier Host-related factors Adherence Tolerability Immunity Genetics Drug pressure Emergence and evolution of drug resistance Virus-related factors Viral load Drug susceptibility Fitness Persistent virus replication during HAART

Attachment Fusion Release of RNA Reverse transcription Integration Transcription Maturation and budding Assembly

Characteristics of HIV-1 infection 1.High virus replication rate ( virus particles / day) 2.Rapid virus clearance (T ½ cells producing virus: <1 day; T ½ free virus in plasma: a few hrs) 3.Virus latency (1:10 6 resting CD4 T cells) 4.Chronic immune activation and inflammation 5.CD4 T-cell depletion ( cells lost daily) 6.Progressive immune deficient state 7.Continuous virus genetic evolution Wong 1997; Chun 1997; Siliciano 2003; Strain 2003; Han 2007

Mechanisms of HIV genetic evolution 1.RT-driven mutagenesis –Rate: ~1 wrong incorporation per genome round –All possible point mutations generated daily 2. APOBEC-driven mutagenesis –Deamination of cytosine residues in nascent DNA –G A hypermutation 3. Recombination –Rate: 7-30 per genome round –Hybrid virus progeny produced from different strains

Dominant quasispecies Escape from pressure Preserved fitness rapid turnover rapid adaptation

Consequences of HIV genetic variability At the population level Continuous emergence of new variants At the patient level Escape from immune pressure Escape from drug pressure Increased fitness and pathogenicity Challenge for diagnostic and monitoring assays

Emergence and evolution of resistance Increasing number of mutations Accumulation of mutations on the same viral genome Initially reduced viral fitness Compensatory changes restore fitness EvolutionEmergence Single mutant Double mutant Triple mutant

Key principles of resistance Drug-resistant mutants are selected (not created) by drug pressure if virological suppression is incomplete Ongoing virus replication under drug pressure leads to the evolution of resistance and cross-resistance Resistant mutants often display reduced fitness but compensatory changes emerge over time that partially restore virus fitness

Plasma HIV RNA Viral gene (e.g., RT) PCR Sequencing Mutations RT M184V Methionine codon 184 of RT ATG / AUG GTG / GUG

Plasma HIV RNA PCR Defective laboratory HIV vector (e.g., RT _ ) Infectious HIV Culture with escalating drug concentrations Fold-changes in IC 50 relative to wild-type M184V = 100 FC for 3TC Viral gene (e.g., RT)

Detection of resistant mutants Detected by ultrasensitive methods Mutation Frequency Detected by routine methods Natural background

Low-frequency resistance in the FIRST study MutationsResistance testP StandardUDS NNRTI 7%15%<0.001 NRTI 6%14%<0.001 PI 2% 5%0.03 Any 14%28%<0.001 N=258 Risk of failure of first-line NNRTI-based ART in patients with NNRTI resistance Bulk resistance: HR 12.4 [ ] UDS resistance: HR 2.5 [ ] Siemen, JID 2009 USD = Ultra deep sequencing

Drug pressure Resistant Wild-type 20-30% Limit of detection

Key principles of resistance Once drug pressure is removed, resistant mutants are outgrown by fitter wild-type virus and become undetectable by routine tests Resistance test results obtained after therapy is discontinued are not reliable Resistant mutants persist at low frequency in plasma and are archived in latently infected cells Resistance is long-lasting Resistance test results must be interpreted in the context of the patients treatment history

Wild-type Resistant Ms S., 35 yr Δ HIV+ Dec 1997 d4T 3TC NVP d4T 3TC NVP VL <50 M184V Y181C M184V Y181C M184V = 3TC, FTC Y181C = NNRTIs

Drug pressure Transmission Transmitted drug resistance Stable after transmission Gradual reversion over time, sometimes incomplete Persistence at low frequency in plasma Persistence in latently infected cells

Genetic barrier Key concepts

Genetic barrier to resistance Defined by: Number of mutations required to compromise activity Impact of each mutation on drug susceptibility Interactions between mutations Fitness cost of resistance Drug concentration Resistant Wild-type

Genetic barrier – A simplified overview ClassARVsGenetic barrier NRTIs ZDV/3TC, d4T/3TC++ ABC/3TC, TDF/3TC+ TDF/FTC++ NNRTIs EFV, NVP, ETV, RPV+ ETV, RPV+/++ PIsBoosted+++/++++ Fusion inhibitorsT20+ CCR5 antagonistsMVC++ (for R5 virus) Integrase inhibitorsRAL, ELV+

Common NRTI resistance patterns NRTIsMutationsZDVd4TABCddITDF3TCFTC ZDV 3TC d4T 3TC M184V TAMs + TAMs d4T 3TC TDF 3TC TDF FTC M184V K65R ABC 3TC M184V L74V K65RY115F TAMs = thymidine analogue mutations: M41L, D67N, K70R, L210W, T215Y/F, L219Q/E

Resistance with first-line HAART StudyARTwkTestsK65RL74VM184VTAMs3 rd drug GS903 n=299TDF 3TC EFV482924%041%0EFV R 55% GS934 n=244TDF FTC EFV %0EFV R 71% GS934 n=243ZDV 3TC EFV %3%EFV R 62% CNA30021 n=770ABC 3TC EFV48383%21%47%0EFV R 58% ABT418 n=190TDF FTC LPV/r %0PI R 0 SOLO n=190ABC 3TC FPV/r %0PI R 0 ARTEMIS n=343TDF FTC DRV/r %0PI R 0 STARTMRK n=281TDF FTC RAL %0RAL R 33% Margot, HIV Med 2006; Margot, JAIDS 2009; Moyle, JAIDS 2005; Molina, IAC 2004; Gathe, AIDS 2004; Mills, AIDS 2009; Lennox, Lamcet 2009.

1 st and 2 nd generation NNRTIs NevirapineEfavirenzEtravirine Major resistance mutations L100I, K101E/P K103N/S V106A/M E138K, V179F Y181C/I/V, Y188L/H/C, G190A/S/E F227C, M230L, K238T Rilpivirine

Activity of ETV with a strong backbone DUET studies: OBR (with DRV/r) + ETV or Placebo % p<0.0001* Responders (%) ± 95% CI Time (weeks) Patients with VL <50 copies/ml at wk 48 (ITT-TLOVR) ETV + OBR (n=599) Placebo + OBR (n=604) 61% Katlama, AIDS 2009 ART-experienced patients with documented NNRTI and PI resistance

Activity of ETV with a weak backbone Study TMC125-C227: 2 NRTIs + ETV or PI Ruxrungtham, HIV Med 2008 ART-experienced, PI-naive patients with documented NNRTI resistance

The genetic barrier of PIs in vitro De Meyer, Antimicrob Agents Chemother 2005; De Meyer, IHDRW 2006 Time (days) Increase in PI selection concentration DRV (R41T, K70E) RTV (G16E, M46I, V82F, I84V) SQV (G48V, A71V, G73S, I84V, L90M) NFV (L10F, D30N, R41K, K45I, M46I, V77I, I84V, N88D) APV (L10F, V32I, L33F, M46I, I47V, I50V) LPV (L10F, L23I, M46I, I50V, I54V, L63P, V82A) TPV (L33V, M46L, V82T) ATV (L10F, V32I, M46I, I62V, A71V, I84V, N88S)

Emergence of PI mutation with DRV/r vs LPV/r TITAN study: OBR + DRV/r or LPV/r 1 Johnson et al. Top HIV Med 2007; Primary PI mutations 1 NRTI RAMs 1 VFs with developing mutations (%) 40 DRV/r LPV/r p 0.05* 6/39 (15%) 24/72 (33%) 3/39 (8%) 19/72 (26%) p 0.05* *Exact Chi-Squared Test; TITAN 96 week analysis De Meyer, HIV TITAN 96 week analysis ART-experienced, LPV- and DRV-naive patients

Hypersusceptibility Key concepts

Mechanisms of NRTI resistance: Primer unblocking T215Y-mediated resistance Hydrolytic removal of the chain-terminating NRTI enables DNA synthesis to resume The pyrophosphate donor in most cells is ATP M184V antagonizes the process 3TC partially restores susceptibility to ZDV, d4T and TDF in the presence of TAMs 3TC antagonizes the emergence of TAMs P P P P P P P P P P P P P P P P Gotte, J Virol 2000

Residual activity Key concepts

Response Resistance Lower cut-off = Level of resistance beyond which response begins to fall off Upper cut-off = Level of resistance beyond which clinical response is lost Zone of intermediate response Resistance as a continuum

Partial treatment interruption in patients with resistance reveals residual activity Deeks, CROI 2005

Key principles of resistance Resistance moves along a continuum and increasing numbers of mutations lead to progressive loss of responses Residual activity is possible despite the presence of extensive resistance (best evidence for the NRTIs) Resistance carries a fitness cost that reduces viral replication Antagonistic effects between mutations can have beneficial effects

Clinical implications for patients with treatment failure The likelihood of drug-resistance depends upon the drug, the regimen and the level of adherence When selecting a new regimen, aim for at least 2 fully active drugs Avoid functional monotherapy with drugs that have a low genetic barrier If options are limited, exploit residual activity and hypersusceptibility effects – continue the NRTIs rather than stopping therapy

Thank you